Taysha Gene Therapies Balance Sheet Health
Financial Health criteria checks 5/6
Taysha Gene Therapies has a total shareholder equity of $74.9M and total debt of $40.5M, which brings its debt-to-equity ratio to 54.1%. Its total assets and total liabilities are $172.7M and $97.8M respectively.
Key information
54.1%
Debt to equity ratio
US$40.51m
Debt
Interest coverage ratio | n/a |
Cash | US$143.94m |
Equity | US$74.94m |
Total liabilities | US$97.79m |
Total assets | US$172.73m |
Recent financial health updates
Recent updates
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07We're Hopeful That Taysha Gene Therapies (NASDAQ:TSHA) Will Use Its Cash Wisely
Mar 08Taysha and UT Southwestern Medical Center launch innovation fund in gene therapy development push
Jan 13Taysha teams up with AllStripes to advance gene therapy in rare disorder
Jan 04Financial Position Analysis
Short Term Liabilities: TSHA's short term assets ($149.9M) exceed its short term liabilities ($36.8M).
Long Term Liabilities: TSHA's short term assets ($149.9M) exceed its long term liabilities ($61.0M).
Debt to Equity History and Analysis
Debt Level: TSHA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if TSHA's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TSHA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TSHA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 14% each year.